📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 13:47
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Artemis Medicare Q1 PAT Surges 48.3% to ₹31.4 Cr; ₹800 Cr Capex Roadmap Outlined
Artemis Medicare reported a strong Q1 FY27 with consolidated revenue growing 12.7% YoY to ₹287.32 Cr and PAT increasing 48.3% to ₹31.44 Cr. The company has operationalized its 300-bed Raipur facility and is advancing Tower IV in Gurugram (200+ beds) to reach a 2,000-bed target by 2030. Management outlined a ₹800 Cr capex plan over the next three years, funded partly by a proposed QIP. Operational metrics improved with ARPOB reaching ₹85,690, while international patient revenue remained resilient at 27% despite geopolitical headwinds.
Confidence: HIGH
What changedThe company has transitioned from planning to execution on its Raipur facility and has provided a granular breakdown of its ₹800 Cr capex strategy.
Why it mattersThe expansion plan is highly material, with the ₹800 Cr capex representing approximately 74% of TTM revenue, aiming to double bed capacity and potentially expand margins to 23%+ through brownfield efficiencies.
Q1 FY27 PAT Growth (YoY): 48.3%Total Capex Plan (3 Years): ₹800 CrCapex vs TTM Revenue: ~74.3%Q1 EBITDA Margin: 21.5%Target Bed Capacity (2030): 2,000ARPOB: ₹85,690
📅 Short termThe stock may react positively to the strong bottom-line growth and margin expansion, alongside clarity on the expansion roadmap.
📈 Long termStructural growth is expected as the company diversifies beyond Gurugram into Raipur and South Delhi, aiming for a ₹2,000 Cr top line from the flagship facility alone.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of ₹800 Cr capex
- Potential equity dilution from QIP
- Geopolitical risks impacting the 27% international patient revenue stream
Key Highlights
Profit After Tax (PAT) grew 48.3% YoY to ₹31.44 Cr in Q1 FY27
Average Revenue Per Occupied Bed (ARPOB) increased to ₹85,690 from ₹81,248 in previous periods
Detailed ₹800 Cr capex plan includes ₹350-360 Cr for VIMHANS and ₹120 Cr for Tower IV
Targeting 2,000 operational beds by FY30, representing a significant scale-up from current capacity
International patient revenue contributed 27% to the total mix during the quarter
👀 What to Watch
Monitor the occupancy ramp-up at the newly operational Raipur facility and the timeline for regulatory clearances for Tower IV in Gurugram. Watch for the pricing and dilution impact of the upcoming QIP intended to fund the ₹800 Cr expansion.
48.3% PAT Growth in Q1 FY27; Artemis Reports Consolidated Revenue of ₹287 Cr
Artemis Medicare reported a strong start to FY27 with consolidated revenue growing 12.7% YoY to ₹287.32 Cr. Profitability outperformed revenue growth significantly, with EBITDA rising 27.9% to ₹61.82 Cr and PAT jumping 48.3% to ₹31.44 Cr. The flagship Gurgaon hospital remains the primary driver, showing improved bed utilization of 65.7% and a higher ARPOB of ₹85,690. A key strategic milestone was reached with the commencement of operations at the Raipur hospital in July 2026, marking the company's expansion beyond its core Delhi-NCR hub.
Confidence: HIGH
What changedArtemis delivered a high-growth quarter with significant margin expansion and successfully operationalized its first major expansion outside the Gurgaon hub in Raipur.
Why it mattersThe sharp rise in PAT and EBITDA margins (reaching ~21.5% this quarter vs 17.5% TTM) demonstrates strong pricing power and efficiency. The Raipur expansion is a critical test of the company's ability to scale its brand geographically.
Consolidated Revenue (Q1 FY27): ₹287.32 CrConsolidated PAT (Q1 FY27): ₹31.44 CrARPOB (Gurgaon): ₹85,690EBITDA Growth (YoY): 27.9%Q1 Revenue vs TTM Revenue: 26.7%Overseas Revenue Contribution: 27.5%
📅 Short termThe stock is likely to react positively to the substantial earnings beat and margin expansion, alongside the positive news of the Raipur hospital commencement.
📈 Long termThe company is transitioning from a single-asset flagship model to a multi-city healthcare platform; success in Raipur and upcoming Delhi projects will be structural re-rating catalysts.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High geographical concentration in Gurgaon (~97% of Q1 revenue)
- Potential short-term margin pressure from Raipur hospital ramp-up
- Significant reliance on international medical travel (27.5% of revenue)
Key Highlights
Consolidated PAT increased 48.3% YoY to ₹31.44 Cr, driven by operational leverage.
Average Revenue Per Occupied Bed (ARPOB) rose 7.4% YoY to ₹85,690 at the Gurgaon facility.
Bed capacity utilization improved to 65.7% from 61.2% in the same quarter last year.
Overseas patient revenue grew 8.6% to ₹76.51 Cr, contributing 27.5% to total operations.
Raipur hospital operations officially commenced in July 2026 to drive regional growth.
👀 What to Watch
Monitor the occupancy ramp-up and break-even timeline for the new Raipur facility, as initial costs may impact consolidated margins. Watch for the execution of planned greenfield/brownfield projects in Delhi to further diversify the revenue base.
48.3% PAT Growth in Q1 FY27; ARPOB Rises to ₹85,690 as Margins Expand to 21.5%
Artemis Medicare reported a strong Q1 FY27 with consolidated revenue growing 12.7% YoY to ₹287.32 cr and PAT surging 48.3% to ₹31.44 cr. Operational efficiency improved significantly as EBITDA margins expanded by 256 bps to 21.5%, driven by operating leverage. The flagship Gurgaon facility saw an 11.4% increase in inpatient volumes and a 7.4% rise in ARPOB to ₹85,690. The company recently operationalized a 300+ bed hospital in Raipur in July 2026 and is targeting a total capacity of 2,000 beds by 2030.
Confidence: HIGH
What changedStrong quarterly earnings performance with significant margin expansion and the commencement of the Raipur facility.
Why it mattersDemonstrates strong operating leverage and pricing power in the premium Delhi-NCR market while beginning geographic diversification.
Q1 Revenue: ₹287.32 crQ1 Revenue vs TTM: ~26.7%PAT Growth (YoY): 48.3%ARPOB (Gurgaon): ₹85,690New Raipur Capacity: 300+ bedsTarget Bed Capacity: ~2,000 beds
📅 Short termPositive reaction expected due to strong margin expansion and PAT growth significantly outpacing revenue growth.
📈 Long termStructural growth driven by doubling capacity from ~1,000 to 2,000 beds and focus on high-acuity specialties.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependence on the Gurgaon facility
- International patient revenue concentration (27%)
Key Highlights
Consolidated PAT grew 48.3% YoY to ₹31.44 cr in Q1 FY27.
EBITDA margins expanded 256 bps YoY to 21.5% from 19.0%.
ARPOB at the Gurgaon facility reached ₹85,690, a 7.4% YoY increase.
Inpatient (IP) volumes increased 11.4% YoY to 9,181 patients.
Raipur hospital (300+ beds) commenced operations in July 2026.
👀 What to Watch
Watch for the occupancy ramp-up at the new Raipur facility and progress on the 650+ bed South Delhi hospital project.
200+ Bed Expansion: Artemis to Invest Rs 160-180 Cr in Gurugram Flagship Hospital
Artemis Medicare has approved a significant expansion of its flagship Gurugram hospital by adding 200+ beds through Tower IV. The project involves an investment of Rs 160-180 crore, representing approximately 15-17% of its TTM revenue, to be funded via internal accruals and debt. The expansion focuses on high-margin quaternary pediatric and advanced gynecology services with a 2-year execution timeline. Simultaneously, the company reported Q1 FY27 consolidated revenue of Rs 287.32 crore, a 12.7% increase over the same quarter last year.
Confidence: HIGH
What changedThe board has formally approved a brownfield expansion (Tower IV) at its primary Gurugram site and released Q1 FY27 financial results showing steady growth.
Why it mattersThe expansion targets high-value specialties in the premium Delhi-NCR market, which could further enhance the company's already strong ARPOB of Rs 81,248 and provide long-term revenue visibility.
Proposed Bed Addition: 200+ bedsInvestment Value: Rs 160 - 180 CrInvestment vs TTM Revenue: ~16.7%Q1 FY27 Revenue (Consolidated): Rs 287.32 CrCurrent Capacity Utilization: 65.7%Execution Timeline: ~2 years
📅 Short termThe announcement of growth-oriented capex alongside steady quarterly results is likely to be viewed positively by the market in the coming weeks.
📈 Long termThis expansion structurally strengthens Artemis's position in the NCR healthcare market and supports its strategy of focusing on complex, high-margin clinical procedures.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk over the 2-year construction period
- Potential margin pressure from increased depreciation and interest costs
- High geographic concentration in Gurugram
Key Highlights
Proposed addition of 200+ beds to the flagship Gurugram facility focusing on pediatric and women's health
Estimated investment of Rs 160 - 180 crore, roughly 17% of TTM revenue
Project completion timeline estimated at approximately 2 years
Q1 FY27 capacity utilization reported at 65.7% for the flagship hospital
Consolidated revenue for Q1 FY27 reached Rs 287.32 crore compared to Rs 254.96 crore in Q1 FY26
👀 What to Watch
Monitor the execution timeline of Tower IV and the ramp-up of Tower 3 which was recently operationalized. Investors should also track the impact of new debt on the company's currently low D/E ratio of 0.28.
Artemis Medicare Q1 PAT up 45% YoY; Announces ₹180 Cr Expansion for 200+ Beds
Artemis Medicare reported a strong Q1 FY27 with consolidated revenue reaching ₹287.32 Cr, a 12.7% increase from ₹254.96 Cr in Q1 FY26. Standalone net profit grew 45% YoY to ₹31.05 Cr, driven by improved operational efficiencies and a capacity utilization of 65.7%. The Board approved a significant expansion of its flagship Gurugram hospital (Tower IV), adding 200+ beds with an investment of ₹160-180 Cr. This expansion, funded via internal accruals and debt, represents approximately 19% of the company's current net worth.
Confidence: HIGH
What changedArtemis has transitioned from planning to formalizing a major capacity expansion in Gurugram while delivering double-digit earnings growth.
Why it mattersThe expansion targets high-demand quaternary pediatric and women's health services, allowing the company to scale its flagship hub where utilization is already healthy at 65.7%.
Q1 Consolidated Revenue: ₹287.32 CrQ1 Standalone PAT: ₹31.05 CrProposed Expansion Capex: ₹180 CrCapex vs Net Worth: 19.16%Proposed Bed Addition: 200+ unitsCapacity Utilization: 65.7%
📅 Short termThe stock is likely to react positively to the 45% YoY profit growth and the clear roadmap for capacity addition which addresses future growth constraints.
📈 Long termThe addition of 200+ beds in Gurugram and the phased 650+ bed expansion in Delhi (Vimhans) by FY29 suggests a structural shift toward becoming a much larger multi-hub healthcare provider.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk over the 2-year construction period
- Potential margin sensitivity to international medical travel volumes
- Increased debt levels to fund the ₹180 Cr capex
Key Highlights
Consolidated revenue for Q1 FY27 stood at ₹287.32 Cr compared to ₹254.96 Cr in Q1 FY26.
Standalone Net Profit increased to ₹31.05 Cr from ₹21.42 Cr in the corresponding previous quarter.
Approved ₹160-180 Cr investment for Tower IV in Gurugram to add 200+ beds for pediatric and gynecology services.
Capacity utilization for the flagship hospital was reported at 65.7% for the quarter ended June 30, 2026.
International patient revenue contributed ₹76.51 Cr, representing approximately 26.6% of total consolidated revenue.
👀 What to Watch
Monitor the execution timeline of the 24-month Tower IV expansion and the progress of the 650+ bed Vimhans project slated for FY29. Investors should also track the stability of international patient contributions, which remain a high-margin segment.
Artemis Medicare Shareholders Approve Fundraise; 98.68% Votes in Favor
Shareholders of Artemis Medicare Services Limited have passed a special resolution to raise funds through the issuance of equity shares or other eligible securities. The resolution received overwhelming support with 98.68% of the total 11.94 crore votes cast in favor. This approval provides the board with the mandate to secure capital for the company's stated growth objectives, including the acquisition of the remaining 35% stake in its cardiac centers and expansion into new geographies like Raipur and Delhi. The promoter group showed unanimous support, voting 100% in favor of the proposal.
Confidence: HIGH
What changedShareholders have officially granted the company the authority to raise capital, moving the proposed fundraise from a board proposal to an actionable corporate event.
Why it mattersThis capital is critical for Artemis to execute its growth strategy, specifically the 100% acquisition of its cardiac centers to improve operational efficiency and its expansion beyond the Gurugram hub into Raipur and Delhi.
Votes in Favor: 98.68%Total Votes Polled: 11,93,90,718Promoter Votes in Favor: 100.00%Institutional Votes in Favor: 92.79%Fundraise Amount: not disclosed
📅 Short termThe successful passing of the resolution is a positive signal of shareholder confidence, though the immediate stock impact will depend on the eventual pricing and size of the fundraise.
📈 Long termIf the funds are deployed effectively into the planned cardiac center consolidation and geographic expansion, it could support the company's 13.8% expected growth rate and improve margins.
⚠ Risk flags
- Equity dilution for existing shareholders
- Execution risk in new geographies (Raipur/Delhi)
- Pricing of the new securities
Key Highlights
98.68% of total valid votes (11,78,18,779 votes) were cast in favor of the fundraise resolution
100% of the promoter and promoter group votes (9,24,39,640 shares) supported the proposal
92.79% of institutional shareholders voted in favor, representing 2.01 crore institutional votes
The voting process involved 35,361 total shareholders as of the June 12, 2026 cut-off date
Only 1.32% of total votes (15.71 lakh votes) were cast against the resolution
👀 What to Watch
Investors should monitor upcoming board meetings for announcements regarding the specific quantum of funds to be raised, the instrument type (e.g., QIP, Rights Issue), and the issue price, as these will determine the extent of equity dilution.
300+ Bed Hospital Operations Commence in Raipur; Bed Capacity Increases by ~43%
Artemis Medicare has operationalized its 300+ bed multi-specialty hospital in Raipur, Chhattisgarh, as of July 9, 2026. This facility operates under a long-term Operations & Management (O&M) agreement, representing a significant asset-light expansion beyond its 700-bed Gurugram hub. The addition increases the company's total bed capacity by approximately 43%, aligning with its strategy to diversify geographically into Central India. Investors should note this move aims to reduce geographic concentration and leverage the company's clinical protocols in a new high-growth market.
Confidence: HIGH
What changedArtemis has officially transitioned from a Delhi-NCR centric operator to a multi-regional player by starting its first major facility in Central India.
Why it mattersThis expansion reduces dependence on the Gurugram hub and utilizes an asset-light O&M model, which can potentially improve Return on Capital Employed (ROCE) if the unit reaches profitability quickly.
New Bed Capacity: 300+ bedsExisting Bed Capacity: 700+ bedsCapacity Increase vs Existing: ~43%TTM Revenue: Rs 1076 CrCommencement Date: July 9, 2026
📅 Short termPositive sentiment is expected as the company meets its expansion timeline; however, initial quarters may see minor margin drag due to start-up costs and marketing.
📈 Long termStructurally significant as it validates the company's ability to scale outside its home market; successful execution could lead to further O&M-based expansions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in a new geography
- Potential for lower ARPOB in Raipur compared to the Gurugram average of Rs 81,248
- Competition from established local healthcare providers
Key Highlights
Commencement of operations for a 300+ bed multi-specialty hospital in Raipur effective July 9, 2026.
The facility increases total bed capacity by ~43% compared to the existing 700-bed flagship Gurugram hospital.
Operated under a long-term Operations & Management (O&M) and Medical Services Agreement, minimizing upfront capex.
The hospital features specialized units in cardiology, oncology, neurosciences, and orthopaedics to serve Chhattisgarh and neighboring states.
👀 What to Watch
Monitor the occupancy ramp-up and Average Revenue Per Occupied Bed (ARPOB) at the Raipur facility over the next 2-4 quarters to assess its contribution to the TTM revenue of Rs 1076 Cr.
Artemis Medicare Announces Final Dividend of ₹0.45 per Share for FY 2025-26
Artemis Medicare Services Limited has recommended a final dividend of ₹0.45 per equity share (face value ₹1) for the financial year 2025-26. The company has fixed July 10, 2026, as the record date to determine eligible shareholders. This communication specifically outlines the Tax Deduction at Source (TDS) requirements, noting a 10% rate for resident shareholders with valid PAN and 20% for those without. Non-resident shareholders may opt for Double Taxation Avoidance Agreement (DTAA) benefits by submitting required documentation by July 15, 2026.
Key Highlights
Recommended final dividend of ₹0.45 per equity share for FY 2025-26.
Record date for dividend entitlement is set for Friday, July 10, 2026.
TDS of 10% applicable for resident individuals if total dividend exceeds ₹10,000 in the tax year.
Non-resident withholding tax is set at 20% plus applicable surcharge and cess, subject to DTAA claims.
Deadline for submission of tax-related documents to the RTA is Wednesday, July 15, 2026.
👀 What to Watch
Shareholders should ensure their PAN and bank account details are updated with their Depository Participant or RTA and submit tax exemption forms like Form 121 by July 15, 2026, to avoid higher tax withholding.
Artemis Medicare Sets July 10 as Record Date for Re 0.45 Final Dividend
Artemis Medicare Services Limited has declared a final dividend of Re. 0.45 per equity share for the financial year 2025-26, which is 45% of the face value of Re. 1. The company has fixed July 10, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to approval at the upcoming 22nd Annual General Meeting (AGM) scheduled for July 31, 2026. Once approved, the payment will be processed within 30 days of the AGM date.
Key Highlights
Final dividend of Re. 0.45 per equity share (45% payout) for FY 2025-26
Record date for dividend eligibility fixed as Friday, July 10, 2026
22nd Annual General Meeting (AGM) to be held on July 31, 2026
Remote e-voting period scheduled from July 28 to July 30, 2026
Dividend payment to be completed within 30 days of shareholder approval
👀 What to Watch
Investors looking to qualify for the dividend should ensure they hold the shares in their demat account before the ex-dividend date, which typically precedes the July 10 record date. Long-term investors should note the steady payout as a sign of consistent shareholder returns.
Artemis Medicare Sets July 10 as Record Date for Re 0.45 Dividend; AGM on July 31
Artemis Medicare Services Limited has announced its 22nd Annual General Meeting (AGM) for July 31, 2026. The company has fixed July 10, 2026, as the record date for a final dividend of Re. 0.45 per equity share (45% of face value) for FY 2025-26. This dividend is subject to shareholder approval at the upcoming AGM and will be paid within 30 days of the meeting. Additionally, the company has outlined key dates for e-voting and annual report distribution.
Key Highlights
Final dividend of Re. 0.45 per equity share (45% of face value Re. 1/-) recommended for FY 2025-26.
Record date for dividend eligibility is fixed as Friday, July 10, 2026.
22nd Annual General Meeting scheduled for July 31, 2026, at 3:00 P.M. via video conferencing.
Remote e-voting period starts on July 28 and ends on July 30, 2026.
Cut-off date for e-voting eligibility is July 24, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the record date of July 10, 2026. Shareholders should also review the upcoming Annual Report for detailed financial performance of FY 2025-26.
Artemis Medicare Services Seeks Shareholder Approval to Raise up to ₹700 Crore
Artemis Medicare Services Limited has issued a postal ballot notice to seek shareholder approval for raising funds up to ₹700 crore. The capital is intended to be raised through the issuance of equity shares, convertible debentures, or other eligible securities via QIP, preferential issue, or private placement. The e-voting period for this special resolution is set from June 19, 2026, to July 18, 2026. This significant fundraise points toward potential expansion plans or strengthening of the company's balance sheet.
Key Highlights
Proposed fundraise of an aggregate amount not exceeding ₹700 crore.
Issuance methods include Qualified Institutions Placement (QIP), preferential issue, and private placement.
The company may offer a discount of up to 5% on the floor price calculated as per SEBI ICDR Regulations.
Remote e-voting period starts on June 19, 2026, and concludes on July 18, 2026.
The resolution is proposed as a Special Resolution, requiring a 75% majority for approval.
👀 What to Watch
Investors should watch for the voting results and subsequent management commentary on the specific utilization of these funds. While equity issuance may lead to dilution, the scale of the fundraise suggests aggressive growth or acquisition plans in the healthcare sector.
Artemis Medicare Board Approves Fundraise Up To Rs. 700 Crores Via Equity Issuance
The Board of Artemis Medicare Services has approved a proposal to raise funds up to Rs. 700 crores through the issuance of equity shares or other eligible securities. This decision follows a prior intimation from February 2026 and will require shareholder approval via a postal ballot. The capital infusion is likely intended for expansion or debt restructuring, though specific utilization details are pending. The board has approved the draft Postal Ballot Notice to be circulated to members in due course.
Key Highlights
Fundraising limit set at an aggregate amount not exceeding Rs. 700 crores.
Issuance may include Equity Shares and/or other eligible securities under SEBI regulations.
Shareholder approval to be sought via Postal Ballot as per the Board's decision on June 4, 2026.
The board meeting commenced at 4:30 PM and concluded at 6:00 PM.
👀 What to Watch
Investors should monitor the upcoming Postal Ballot notice for specific details on fund utilization and potential equity dilution. While the fundraise signals growth intent, the pricing of the issuance will be a key factor for short-term stock movement.
Artemis Medicare FY26 PAT Jumps 26% to ₹104 Cr; Plans Expansion to 2,000 Beds by 2029
Artemis Medicare reported a strong FY26 with consolidated revenue growing 15.4% to INR 1,081 crores and PAT increasing 26.2% to INR 104 crores. The company maintained robust EBITDA margins of 20.2% for the full year, driven by high-complexity procedures and a strong international patient mix contributing 31% of revenue. Management outlined a clear growth path to increase bed capacity from 800 to 2,000 by 2029, supported by a board-approved INR 700 crore fundraise. Key upcoming milestones include the commissioning of the 300-bed Raipur facility in Q1 FY27.
Key Highlights
FY26 consolidated revenue reached INR 1,081 crores with a 20.2% EBITDA margin and PAT of INR 104 crores.
Q4 FY26 PAT grew 32.1% YoY to INR 30 crores, with ARPOB rising 7.3% to INR 84,571.
International patient revenue grew 26.9% YoY, maintaining a high contribution of 31% to total revenue.
Aggressive expansion plan to reach 2,000 beds by 2029, including new facilities in Raipur (300 beds) and South Delhi (650 beds).
Board approved fundraising of up to INR 700 crores to support upcoming capital expenditure and growth initiatives.
👀 What to Watch
Investors should monitor the timely commissioning of the Raipur facility in Q1 FY27 and the execution of the INR 700 crore fundraise. The company's ability to maintain high ARPOB and a strong international patient mix makes it a robust play in the premium healthcare segment.
Artemis Medicare FY26 Results: Recommends 45% Dividend and Appoints New Independent Directors
Artemis Medicare Services Limited has recommended a final dividend of ₹0.45 per equity share (45% of face value) for the financial year ended March 31, 2026. The board has strengthened its leadership by appointing Mr. Tapan Mitra and proposing Dr. Girdhar J. Gyani as Independent Directors for three-year terms. Additionally, the company has extended the utilization period for unspent funds from its preferential issue by 18 months to ensure strategic capital deployment. The statutory auditors, M/s. T R Chadha & Co LLP, have also been re-appointed for a second five-year term.
Key Highlights
Recommended a final dividend of ₹0.45 per equity share of face value ₹1 (45% payout)
Appointed Mr. Tapan Mitra as Additional Independent Director for a 3-year term effective May 8, 2026
Proposed Dr. Girdhar J. Gyani as Independent Director for a 3-year term starting August 1, 2026
Extended the utilization period of unspent preferential issue funds by 18 months without changing objects
Re-appointed M/s. T R Chadha & Co LLP as Statutory Auditors for a second term of 5 years
👀 What to Watch
Investors should monitor the full financial results for revenue growth and margin trends, while the dividend and board strengthening reflect stable corporate governance.
Artemis Q4 FY26 Net Profit Surges 32.1% to ₹30.3 Cr; Revenue Up 16.4%
Artemis Medicare reported a strong Q4 FY26 with consolidated net profit growing 32.1% YoY to ₹3,028 Lacs. Revenue from operations increased by 16.4% to ₹27,923 Lacs, driven by higher ARPOB and international patient contributions. For the full year FY26, the company crossed the ₹1,000 crore revenue milestone, reaching ₹1,08,124 Lacs with a 26.2% growth in PAT. Operational efficiency at the flagship Gurgaon facility remains high, with ARPOB rising to ₹84,571 in Q4.
Key Highlights
Consolidated Q4 FY26 Net Profit rose 32.1% YoY to ₹3,028 Lacs, while EBITDA grew 23.1% to ₹5,938 Lacs.
Average Revenue Per Occupied Bed (ARPOB) increased to ₹84,571 in Q4 FY26 from ₹78,835 in the previous year.
International patient revenue contributed 30.8% to the total net revenue in Q4, growing 13.5% YoY.
Full-year FY26 consolidated revenue grew 15.4% to ₹1,08,124 Lacs with PAT reaching ₹10,372 Lacs.
Bed capacity utilization stood at 64.6% for Q4, with the company progressing on its Raipur facility expansion.
👀 What to Watch
Investors should view the strong growth in ARPOB and international patient mix as positive indicators of margin expansion. The upcoming Raipur facility provides a clear growth catalyst for the next fiscal year.
Artemis Medicare Q4 FY26 PAT Jumps 32% YoY; Revenue Crosses INR 1,000 Cr in FY26
Artemis Medicare reported a strong financial performance for FY26, with consolidated revenue growing 15.4% to INR 1,081 crore and PAT increasing 26.2% to INR 104 crore. The company's core Gurgaon facility saw a 9.2% growth in inpatient volumes and a 7.3% rise in ARPOB to INR 84,571 in Q4. Management has outlined an aggressive expansion plan to reach approximately 2,000 beds by 2028, supported by a proposed INR 700 crore fundraise. Profitability margins showed healthy improvement, with Q4 EBITDA margins expanding to 21.3%.
Key Highlights
Consolidated PAT for FY26 rose 26.2% YoY to INR 10,372 Lacs, with Q4 PAT growing 32.1% to INR 3,028 Lacs.
Annual consolidated revenue from operations surpassed the INR 1,000 Cr milestone, reaching INR 1,08,124 Lacs.
Operational efficiency improved as Q4 EBITDA margins expanded by 116 bps YoY to 21.3%.
Aggressive expansion strategy targeting 2,000 beds by 2028, including a new 300+ bed hospital in Raipur expected by June 2026.
Average Revenue Per Occupied Bed (ARPOB) for the Gurgaon facility grew 7.3% YoY to INR 84,571 in Q4 FY26.
👀 What to Watch
Investors should view the strong growth in ARPOB and inpatient volumes as a sign of robust demand and operational efficiency. Monitor the execution of the Raipur and South Delhi expansion projects and the terms of the proposed INR 700 crore fundraise as key growth drivers.
Artemis Medicare Recommends ₹0.45 Final Dividend and Extends Fund Utilization Period
Artemis Medicare Services has recommended a final dividend of ₹0.45 per share (45% of face value) for the financial year ended March 31, 2026. The board has also approved an 18-month extension for the utilization of unutilized funds from a previous preferential issue, maintaining the original objects. Key leadership updates include the appointment of Mr. Tapan Mitra and the proposed appointment of Dr. Girdhar J. Gyani as Independent Directors. Additionally, the company has proposed the re-appointment of its statutory auditors for a second five-year term until 2031.
Key Highlights
Recommended a final dividend of ₹0.45 per equity share (45% of face value ₹1) for FY26.
Approved an 18-month extension for the utilization of unutilized funds from the preferential issue.
Appointed Mr. Tapan Mitra as an Independent Director for a 3-year term starting May 8, 2026.
Proposed re-appointment of M/s. T R Chadha & Co LLP as Statutory Auditors for a 5-year term until 2031.
👀 What to Watch
Investors should note the dividend payout and the extension of capital deployment timelines for preferential issue funds. Monitor the upcoming Annual General Meeting for final approvals on these resolutions.
Artemis Medicare Reports FY26 Results, Recommends ₹0.45 Dividend
Artemis Medicare Services Limited has approved its audited financial results for the fiscal year ended March 31, 2026. The Board has recommended a final dividend of ₹0.45 per equity share (45% of face value), subject to shareholder approval. Key governance updates include the appointment of Mr. Tapan Mitra and Dr. Girdhar J. Gyani as Independent Directors. Notably, the company has extended the timeline for utilizing unutilized funds from its preferential issue by 18 months, indicating a delay in capital deployment for its stated objects.
Key Highlights
Recommended a final dividend of ₹0.45 per equity share of face value ₹1 (45%) for FY26.
Appointed Mr. Tapan Mitra as an Independent Director for a period of 3 years effective May 8, 2026.
Approved an 18-month extension for the utilization of unutilized funds from the preferential issue.
Proposed re-appointment of M/s. T R Chadha & Co LLP as Statutory Auditors for a second 5-year term.
Financial results for the quarter and year ended March 31, 2026, received an unmodified audit opinion.
👀 What to Watch
Investors should analyze the full financial statements to assess revenue and margin trends for FY26. The 18-month extension for fund utilization warrants a closer look at the company's expansion or capital expenditure timelines.
Artemis Medicare to Manage 650+ Bed VIMHANS Hospital; Plans ₹520 Cr CAPEX
Artemis Medicare has entered into a long-term Medical Services Agreement to operate and manage the VIMHANS hospital in South Delhi. The project involves a phased investment of ₹500-520 crore, with the first 450 beds expected to be operational by FY29. This strategic move targets a high-ARPOB (Average Revenue per Occupied Bed) micro-market and will nearly double the company's existing capacity of approximately 800 beds. The agreement spans an initial 15 years, extendable by another 15 years, significantly strengthening Artemis's footprint in the Delhi NCR healthcare sector.
Key Highlights
Addition of 650+ beds in prime South Delhi location, nearly doubling current ~800-bed capacity
Total planned CAPEX of ₹500-520 crore (₹75-80 lakh per bed) funded via internal accruals and debt
Phase 1 commissioning of 450 beds targeted for FY29, with subsequent expansion to 650+ beds
Long-term exclusive management rights for 15 years, extendable by another 15 years at company's option
Strategic focus on high-margin specialties including neurosciences, oncology, and robotic surgery
👀 What to Watch
This expansion is a significant long-term growth driver in a high-demand market, though the FY29 operational timeline implies a long gestation period. Investors should monitor the company's debt levels and execution milestones over the next three years.
Delhi High Court Dismisses ₹3.92 Crore PF Dispute Against Artemis Medicare
Artemis Medicare Services Limited has successfully defended a legal challenge regarding a ₹3.92 crore provident fund demand. The Delhi High Court dismissed a writ petition filed by the Regional Provident Fund Commissioner that sought to overturn a previous favorable tribunal ruling. This decision confirms the setting aside of the original demand issued in January 2021. The resolution of this litigation removes a potential financial liability and legal overhang for the company.
Key Highlights
Delhi High Court dismissed the writ petition filed by the Regional Provident Fund Commissioner on January 28, 2026
The litigation concerned a demand for ₹3.92 crores in outstanding provident fund contributions
The ruling upholds a February 2023 decision by the Central Government Industrial Tribunal (CGIT) in favor of the company
The dismissal was based on jurisdictional grounds raised by Artemis Medicare
👀 What to Watch
This is a positive outcome that clears a legal hurdle and a ₹3.92 crore contingent liability. Investors can remain confident in the company's ability to manage regulatory disputes effectively.
